Abbisko Cayman Limited (2256.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
281
First IPO Date
October 13, 2021
| Name | Title | Pay | Year Born |
| Yao-Chang Xu | Founder, Chairman of the Board & Chief Executive Officer | 5.06M | 1957 |
| Hongping Yu | Co-Founder, SVP of Chemistry, Chief Scientific Officer & Executive Director | 3.43M | 1968 |
| Jing Ji | Chief Medical Officer & Executive Director | 5.77M | 1970 |
| Zhen Zhang | Senior VP of CMC & Head of Chemistry, Manufacturing and Controls | 0 | 1973 |
| Zidong Zhang | Group Chief Financial Officer | 0 | 1981 |
| Hanxi Zhang | Joint Company Secretary | 0 | N/A |
| Jia Feng | Vice President of HR and Operations & Head of Human Resource | 0 | N/A |
| Yongyi Li | General Counsel | 0 | 1976 |
| Sio Ngo Lin | Joint Company Secretary | 0 | N/A |
| Yin Wah Chan FCCA FCIS HKICS | Joint Company Secretary | 0 | 1975 |
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.